News

Galvokamig, a biologic targeting IL-13 and IL-17A/F, demonstrated significant benefits in moderate to severe atopic dermatitis.

Late-breaking EADV 2025 presentations highlighted positive efficacy outcomes in the adolescent population and pooled safety data across 5 phase 2b and phase 3 trials of delgocitinib cream.

Tiffany Mayo, MD, recently moderated a Dermatology Times Case-Based Roundtable event to discuss topical innovation, systemic options, and patient-centered factors when treating atopic dermatitis.

Together with earlier trials presented at EADV, these findings support OX40 receptor inhibition as a promising therapeutic approach for AD.

The oral degrader produced biomarker reductions consistent with or superior to dupilumab, according to data presented at EADV 2025.

At EADV 2025, she showcased how OX40 and JAK inhibition offer complementary approaches to long-term disease control.

Catch up on coverage from the second day of the European Academy of Dermatology and Venereology Congress 2025 held in Paris, France.

Nicole Harter, MD, explores ruxolitinib 1.5% cream for pediatric atopic dermatitis, offering a novel, effective treatment option for children aged 2 to 11.

Denifanstat shows promising results in treating moderate to severe acne vulgaris, achieving significant efficacy and safety at the EADV Congress 2025.

Ruxolitinib cream has become the first topical JAK inhibitor available for pediatric atopic dermatitis (AD) in the US.

Major unmet needs in pediatric AD include rapid itch relief, access, affordability, and better options for sensitive skin.

Findings from a large retrospective study presented at EADV 2025 suggest psoriasis significantly increases the risk of both wet and dry age-related macular degeneration.

LEO Pharma unveils promising phase 2b trial results for temtokibart, showcasing significant improvements in atopic dermatitis at EADV Congress 2025.

Presented at EADV Congress 2025, galvokimig showed promising early results in treating moderate to severe atopic dermatitis, targeting multiple inflammatory pathways for effective relief.

Data presented at EADV 2025 on the ROCKET-SHUTTLE trial demonstrate that rocatinlimab, a T-cell rebalancing therapy, significantly improves the signs and symptoms of moderate to severe AD in adults when used with topical therapies.

Balinatunfib was generally well tolerated, with common adverse events such as nausea and arthralgia also observed in placebo groups, according to data from EADV 2025.

Almirall's POSITIVE study, presented at EADV 2025, prioritizes patient well-being, showcasing the holistic impact of advanced treatments.

A meaningful difference in WI-NRS scores was observed as early as day 3 of treatment with ruxolitinib cream.

Catch up on coverage from the first day of the 2025 European Academy of Dermatology and Venereology Congress held in Paris, France.

At the 2025 EADV Congress in Paris, phase 3 ICONIC-ADVANCE data showed icotrokinra outperformed deucravacitinib in moderate to severe psoriasis.

A new study at EADV 2025 links atopic dermatitis to increased suicidal ideation, highlighting the condition's severe psychological impact.

The trial presented at EADV 2025 confirmed that icotrokinra’s efficacy is consistent with injectable IL-23 inhibitors while offering an oral option.

According to a poster at the 2025 EADV Congress, barzolvolimab achieved comparable improvements in weekly Urticaria Activity Scores across immunoglobulin E (lgE) subgroups.

Sanofi's brivekimig shows promising phase 2a results for hidradenitis suppurativa (HS), offering hope for effective treatment options at EADV Congress 2025.

At EADV 2025, UCB presented new long-term data demonstrating bimekizumab’s durable efficacy and a consistent safety profile over extended treatment.

STOP-HS1 and STOP-HS2 phase 3 trials showed nearly 60% of patients achieving HiSCR50 by week 24, according to a presentation at EADV 2025.

Join Dermatology Times at the EADV Congress 2025 for expert insights and live updates from Paris, France.

By blocking 2 key inflammation signals, research presented at EADV found bimekizumab may help keep both skin and joints healthier over time.

At EADV, research showed benefits of zasocitinib on quality of life were observed as early as week 4 and sustained through week 12.

Nayan Patel, PharmD, reveals how innovative glutathione delivery transforms skin care, combats oxidative stress, and empowers skin health for lasting results.